sample_name	organism	isolate	age	biomaterial_provider	sex	tissue	cell_line	cell_subtype	cell_type	sample_type	trasfected_plasmid	drug	description
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PAO	Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Belinostat (PXD101)	Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Danusertib (PHA-739358)	Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SNS-314 Mesylate	Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM JNJ-7706621	Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CCT129202	Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AG-14361	Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tubastatin A HCl	Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CUDC-907	Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CI994 (Tacedinaline)	Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Entacapone	Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1:1000 DMSO	Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Iniparib (BSI-201)	Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Mocetinostat (MGCD0103)	Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Valproic acid sodium salt (Sodium valproate)	Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Ruxolitinib (INCB018424)	Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Hesperadin	Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM LY2784544	Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM NVP-BSK805 2HCl	Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM MK-5108 (VX-689)	Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM RG108	Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Sodium Phenylbutyrate	Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Mirin	Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PCI-24781 (Abexinostat)	Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SRT1720	Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CYC116	Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Resveratrol	Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM EX 527 (Selisistat)	Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SGI-1776 free base	Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM TG101209	Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM M344	Sample from drug screen treated with 100 nM M344 in position C09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Baricitinib (LY3009104, INCB028050)	Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tranylcypromine (2-PCPA) HCl	Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM DNA-PKi	Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM LAQ824 (Dacinostat)	Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM INO-1001	Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM ENMD-2076	Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Droxinostat	Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Azacitidine	Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AZ 960	Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Resminostat	Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM I-BET151 (GSK1210151A)	Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM WHI-P154	Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM 3-Aminobenzamide	Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Quisinostat (JNJ-26481585)	Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Alisertib (MLN8237)	Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CUDC-101	Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Aurora A Inhibitor I	Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PCI-34051	Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CYT387	Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM TAK-901	Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tofacitinib (CP-690550,Tasocitinib)	Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PJ34	Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Procainamide HCl	Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Rucaparib (AG-014699,PF-01367338)	Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AT9283	Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Decitabine	Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PHA-680632	Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM KW-2449	Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tubacin	Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AMG-900	Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM WP1066	Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM S-Ruxolitinib (INCB018424)	Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tofacitinib (CP-690550) Citrate	Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM MLN8054	Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AG-490 (Tyrphostin B42)	Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PFI-1 (PF-6405761)	Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM MC1568	Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AZD1480	Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AR-42	Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM TG101348 (SAR302503)	Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Sirtinol	Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM IOX2	Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AZD2461	Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM ZM 447439	Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Barasertib (AZD1152-HQPA)	Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM 2-Methoxyestradiol (2-MeOE2)	Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Pracinostat (SB939)	Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Givinostat (ITF2357)	Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Quercetin	Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CCT137690	Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CEP-33779	Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Romidepsin (FK228, Depsipeptide)	Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM XL019	Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Zebularine	Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM OG-L002	Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM TMP269	Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM ZM 39923 HCl	Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Veliparib (ABT-888)	Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CX-6258 HCl	Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM 2,4-Pyridinedicarboxylic Acid	Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM ITSA-1	Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AGK2	Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Oxamflatin	Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM 3-Deazaneplanocin A (DZNeP)	Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SGC-CBP30	Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM EPZ004777	Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SMI-4a	Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM FG-4592	Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BMN 673	Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Garcinol	Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tranylcypromine hemisulfate	Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Salermide	Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Suramin·6Na	Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM EPZ-6438	Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM MM-102	Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM OTX015	Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BIX 01294	Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Panobinostat (LBH589)	Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM EPZ5676	Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Splitomicin	Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Valproic acid	Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM MC-1293	Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BML-278	Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM C646	Sample from drug screen treated with 100 nM C646 in position D02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SGI-1027	Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM UNC669	Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM UPF 1069	Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Trichostatin A (TSA)	Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM GSK J4 HCl	Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BML-210	Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Nicotinamide	Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Anacardic acid	Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM NCH-51	Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM I-BET-762	Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM RG2833 (RGFP109)	Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM ME0328	Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Scriptaid	Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Vorinostat (SAHA, MK0683)	Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM SGC 0946	Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Apicidin	Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BML-266	Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM B2	Sample from drug screen treated with 100 nM B2 in position E10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM NSC-3852	Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM RGFP966	Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM RVX-208	Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Nexturastat A	Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Tubastatin A	Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM VX-680 (Tozasertib, MK-0457)	Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM UNC1215	Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Suberoyl bis-hydroxamic acid	Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Piceatannol	Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BIX-01294·3HCl	Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Aminoresveratrol sulfate	Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Bromosporine	Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM PJ34 HCl	Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Filgotinib (GLPG0634)	Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Lomeguatrib	Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Entinostat (MS-275)	Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM AZD1208	Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Nullscript	Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Fluoro-SAHA	Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Butyrolactone 3	Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM BML-281	Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM IOX1	Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CPI-203	Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Rocilinostat (ACY-1215)	Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Pacritinib (SB1518)	Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Olaparib (AZD2281, Ku-0059436)	Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM (+)-JQ1	Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Isonicotinamide	Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Valproic acid hydroxamate	Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM CTPB	Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	100 nM Triacetylresveratrol	Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Belinostat (PXD101)	Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Danusertib (PHA-739358)	Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SNS-314 Mesylate	Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM JNJ-7706621	Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CCT129202	Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AG-14361	Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tubastatin A HCl	Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CUDC-907	Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CI994 (Tacedinaline)	Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Entacapone	Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Iniparib (BSI-201)	Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Mocetinostat (MGCD0103)	Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Valproic acid sodium salt (Sodium valproate)	Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Ruxolitinib (INCB018424)	Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Hesperadin	Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM LY2784544	Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM NVP-BSK805 2HCl	Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM MK-5108 (VX-689)	Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM RG108	Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Sodium Phenylbutyrate	Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PCI-24781 (Abexinostat)	Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SRT1720	Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CYC116	Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Resveratrol	Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM EX 527 (Selisistat)	Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SGI-1776 free base	Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM TG101209	Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM M344	Sample from drug screen treated with 1 µM M344 in position C09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Baricitinib (LY3009104, INCB028050)	Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tranylcypromine (2-PCPA) HCl	Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM LAQ824 (Dacinostat)	Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM INO-1001	Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM ENMD-2076	Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Droxinostat	Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Azacitidine	Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AZ 960	Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Resminostat	Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM I-BET151 (GSK1210151A)	Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM WHI-P154	Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM 3-Aminobenzamide	Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Quisinostat (JNJ-26481585)	Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Alisertib (MLN8237)	Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CUDC-101	Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Aurora A Inhibitor I	Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PCI-34051	Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CYT387	Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM TAK-901	Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tofacitinib (CP-690550,Tasocitinib)	Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PJ34	Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Procainamide HCl	Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Rucaparib (AG-014699,PF-01367338)	Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AT9283	Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Decitabine	Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PHA-680632	Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM KW-2449	Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tubacin	Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AMG-900	Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM WP1066	Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM S-Ruxolitinib (INCB018424)	Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tofacitinib (CP-690550) Citrate	Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM MLN8054	Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AG-490 (Tyrphostin B42)	Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PFI-1 (PF-6405761)	Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM MC1568	Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AZD1480	Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AR-42	Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM TG101348 (SAR302503)	Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Sirtinol	Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM IOX2	Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AZD2461	Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM ZM 447439	Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Barasertib (AZD1152-HQPA)	Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM 2-Methoxyestradiol (2-MeOE2)	Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Pracinostat (SB939)	Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Givinostat (ITF2357)	Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Quercetin	Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CCT137690	Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CEP-33779	Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Romidepsin (FK228, Depsipeptide)	Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM XL019	Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Zebularine	Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM OG-L002	Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM TMP269	Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM ZM 39923 HCl	Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Veliparib (ABT-888)	Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CX-6258 HCl	Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM 2,4-Pyridinedicarboxylic Acid	Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM ITSA-1	Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AGK2	Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Oxamflatin	Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM 3-Deazaneplanocin A (DZNeP)	Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SGC-CBP30	Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM EPZ004777	Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SMI-4a	Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM FG-4592	Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BMN 673	Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Garcinol	Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tranylcypromine hemisulfate	Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Salermide	Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Suramin·6Na	Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM EPZ-6438	Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM MM-102	Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM OTX015	Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BIX 01294	Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Panobinostat (LBH589)	Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM EPZ5676	Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Splitomicin	Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Valproic acid	Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM MC-1293	Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BML-278	Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM C646	Sample from drug screen treated with 1 µM C646 in position D02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SGI-1027	Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM UNC669	Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM UPF 1069	Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Trichostatin A (TSA)	Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM GSK J4 HCl	Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BML-210	Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Nicotinamide	Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Anacardic acid	Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM NCH-51	Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM I-BET-762	Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM RG2833 (RGFP109)	Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM ME0328	Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Scriptaid	Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Vorinostat (SAHA, MK0683)	Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM SGC 0946	Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Apicidin	Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BML-266	Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM B2	Sample from drug screen treated with 1 µM B2 in position E10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM NSC-3852	Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM RGFP966	Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM RVX-208	Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Nexturastat A	Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Tubastatin A	Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM VX-680 (Tozasertib, MK-0457)	Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM UNC1215	Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Suberoyl bis-hydroxamic acid	Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Piceatannol	Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BIX-01294·3HCl	Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Aminoresveratrol sulfate	Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Bromosporine	Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM PJ34 HCl	Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Filgotinib (GLPG0634)	Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Lomeguatrib	Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Entinostat (MS-275)	Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM AZD1208	Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Nullscript	Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Fluoro-SAHA	Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Butyrolactone 3	Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM BML-281	Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM IOX1	Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CPI-203	Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Rocilinostat (ACY-1215)	Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Pacritinib (SB1518)	Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Olaparib (AZD2281, Ku-0059436)	Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM (+)-JQ1	Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Isonicotinamide	Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Valproic acid hydroxamate	Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM CTPB	Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	1 µM Triacetylresveratrol	Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Belinostat (PXD101)	Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Danusertib (PHA-739358)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Danusertib (PHA-739358)	Sample from drug screen treated with 10 µM Danusertib (PHA-739358) in position A03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM SNS-314 Mesylate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SNS-314 Mesylate	Sample from drug screen treated with 10 µM SNS-314 Mesylate in position A04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM JNJ-7706621	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM JNJ-7706621	Sample from drug screen treated with 10 µM JNJ-7706621 in position A05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT129202	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CCT129202	Sample from drug screen treated with 10 µM CCT129202 in position A06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-14361	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AG-14361	Sample from drug screen treated with 10 µM AG-14361 in position A07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tubastatin A HCl	Sample from drug screen treated with 10 µM Tubastatin A HCl in position A08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-907	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CUDC-907	Sample from drug screen treated with 10 µM CUDC-907 in position A09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CI994 (Tacedinaline)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CI994 (Tacedinaline)	Sample from drug screen treated with 10 µM CI994 (Tacedinaline) in position A10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entacapone	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Entacapone	Sample from drug screen treated with 10 µM Entacapone in position A11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Iniparib (BSI-201)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Iniparib (BSI-201)	Sample from drug screen treated with 10 µM Iniparib (BSI-201) in position B02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Mocetinostat (MGCD0103)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Mocetinostat (MGCD0103)	Sample from drug screen treated with 10 µM Mocetinostat (MGCD0103) in position B03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid sodium salt (Sodium valproate)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Valproic acid sodium salt (Sodium valproate)	Sample from drug screen treated with 10 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Ruxolitinib (INCB018424)	Sample from drug screen treated with 10 µM Ruxolitinib (INCB018424) in position B05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Hesperadin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Hesperadin	Sample from drug screen treated with 10 µM Hesperadin in position B06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM LY2784544	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM LY2784544	Sample from drug screen treated with 10 µM LY2784544 in position B07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM NVP-BSK805 2HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM NVP-BSK805 2HCl	Sample from drug screen treated with 10 µM NVP-BSK805 2HCl in position B08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM MK-5108 (VX-689)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM MK-5108 (VX-689)	Sample from drug screen treated with 10 µM MK-5108 (VX-689) in position B09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG108	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM RG108	Sample from drug screen treated with 10 µM RG108 in position B10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sodium Phenylbutyrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Sodium Phenylbutyrate	Sample from drug screen treated with 10 µM Sodium Phenylbutyrate in position B11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-24781 (Abexinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PCI-24781 (Abexinostat)	Sample from drug screen treated with 10 µM PCI-24781 (Abexinostat) in position C02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM SRT1720	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SRT1720	Sample from drug screen treated with 10 µM SRT1720 in position C03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYC116	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CYC116	Sample from drug screen treated with 10 µM CYC116 in position C04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Resveratrol	Sample from drug screen treated with 10 µM Resveratrol in position C05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM EX 527 (Selisistat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM EX 527 (Selisistat)	Sample from drug screen treated with 10 µM EX 527 (Selisistat) in position C06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1776 free base	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SGI-1776 free base	Sample from drug screen treated with 10 µM SGI-1776 free base in position C07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101209	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM TG101209	Sample from drug screen treated with 10 µM TG101209 in position C08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM M344	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM M344	Sample from drug screen treated with 10 µM M344 in position C09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Baricitinib (LY3009104, INCB028050)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Baricitinib (LY3009104, INCB028050)	Sample from drug screen treated with 10 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine (2-PCPA) HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tranylcypromine (2-PCPA) HCl	Sample from drug screen treated with 10 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM LAQ824 (Dacinostat)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM LAQ824 (Dacinostat)	Sample from drug screen treated with 10 µM LAQ824 (Dacinostat) in position D02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM INO-1001	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM INO-1001	Sample from drug screen treated with 10 µM INO-1001 in position D03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM ENMD-2076	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM ENMD-2076	Sample from drug screen treated with 10 µM ENMD-2076 in position D04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Droxinostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Droxinostat	Sample from drug screen treated with 10 µM Droxinostat in position D05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Azacitidine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Azacitidine	Sample from drug screen treated with 10 µM Azacitidine in position D06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZ 960	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AZ 960	Sample from drug screen treated with 10 µM AZ 960 in position D07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Resminostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Resminostat	Sample from drug screen treated with 10 µM Resminostat in position D08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET151 (GSK1210151A)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM I-BET151 (GSK1210151A)	Sample from drug screen treated with 10 µM I-BET151 (GSK1210151A) in position D09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM WHI-P154	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM WHI-P154	Sample from drug screen treated with 10 µM WHI-P154 in position D10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Aminobenzamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM 3-Aminobenzamide	Sample from drug screen treated with 10 µM 3-Aminobenzamide in position D11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quisinostat (JNJ-26481585)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Quisinostat (JNJ-26481585)	Sample from drug screen treated with 10 µM Quisinostat (JNJ-26481585) in position E02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Alisertib (MLN8237)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Alisertib (MLN8237)	Sample from drug screen treated with 10 µM Alisertib (MLN8237) in position E03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CUDC-101	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CUDC-101	Sample from drug screen treated with 10 µM CUDC-101 in position E04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aurora A Inhibitor I	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Aurora A Inhibitor I	Sample from drug screen treated with 10 µM Aurora A Inhibitor I in position E05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM PCI-34051	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PCI-34051	Sample from drug screen treated with 10 µM PCI-34051 in position E06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CYT387	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CYT387	Sample from drug screen treated with 10 µM CYT387 in position E07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM TAK-901	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM TAK-901	Sample from drug screen treated with 10 µM TAK-901 in position E08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550,Tasocitinib)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tofacitinib (CP-690550,Tasocitinib)	Sample from drug screen treated with 10 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PJ34	Sample from drug screen treated with 10 µM PJ34 in position E10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Procainamide HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Procainamide HCl	Sample from drug screen treated with 10 µM Procainamide HCl in position E11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rucaparib (AG-014699,PF-01367338)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Rucaparib (AG-014699,PF-01367338)	Sample from drug screen treated with 10 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AT9283	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AT9283	Sample from drug screen treated with 10 µM AT9283 in position F03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Decitabine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Decitabine	Sample from drug screen treated with 10 µM Decitabine in position F04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM PHA-680632	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PHA-680632	Sample from drug screen treated with 10 µM PHA-680632 in position F05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM KW-2449	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM KW-2449	Sample from drug screen treated with 10 µM KW-2449 in position F06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubacin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tubacin	Sample from drug screen treated with 10 µM Tubacin in position F07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AMG-900	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AMG-900	Sample from drug screen treated with 10 µM AMG-900 in position F08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM WP1066	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM WP1066	Sample from drug screen treated with 10 µM WP1066 in position F09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM S-Ruxolitinib (INCB018424)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM S-Ruxolitinib (INCB018424)	Sample from drug screen treated with 10 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tofacitinib (CP-690550) Citrate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tofacitinib (CP-690550) Citrate	Sample from drug screen treated with 10 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM MLN8054	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM MLN8054	Sample from drug screen treated with 10 µM MLN8054 in position G02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AG-490 (Tyrphostin B42)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AG-490 (Tyrphostin B42)	Sample from drug screen treated with 10 µM AG-490 (Tyrphostin B42) in position G03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM PFI-1 (PF-6405761)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PFI-1 (PF-6405761)	Sample from drug screen treated with 10 µM PFI-1 (PF-6405761) in position G04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC1568	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM MC1568	Sample from drug screen treated with 10 µM MC1568 in position G05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1480	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AZD1480	Sample from drug screen treated with 10 µM AZD1480 in position G06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AR-42	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AR-42	Sample from drug screen treated with 10 µM AR-42 in position G07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM TG101348 (SAR302503)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM TG101348 (SAR302503)	Sample from drug screen treated with 10 µM TG101348 (SAR302503) in position G08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Sirtinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Sirtinol	Sample from drug screen treated with 10 µM Sirtinol in position G09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM IOX2	Sample from drug screen treated with 10 µM IOX2 in position G10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD2461	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AZD2461	Sample from drug screen treated with 10 µM AZD2461 in position G11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 447439	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM ZM 447439	Sample from drug screen treated with 10 µM ZM 447439 in position H02 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Barasertib (AZD1152-HQPA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Barasertib (AZD1152-HQPA)	Sample from drug screen treated with 10 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2-Methoxyestradiol (2-MeOE2)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM 2-Methoxyestradiol (2-MeOE2)	Sample from drug screen treated with 10 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pracinostat (SB939)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Pracinostat (SB939)	Sample from drug screen treated with 10 µM Pracinostat (SB939) in position H05 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Givinostat (ITF2357)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Givinostat (ITF2357)	Sample from drug screen treated with 10 µM Givinostat (ITF2357) in position H06 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Quercetin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Quercetin	Sample from drug screen treated with 10 µM Quercetin in position H07 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CCT137690	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CCT137690	Sample from drug screen treated with 10 µM CCT137690 in position H08 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM CEP-33779	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CEP-33779	Sample from drug screen treated with 10 µM CEP-33779 in position H09 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Romidepsin (FK228, Depsipeptide)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Romidepsin (FK228, Depsipeptide)	Sample from drug screen treated with 10 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM XL019	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM XL019	Sample from drug screen treated with 10 µM XL019 in position H11 in plate 1
K562 ddCas9 RSTP2 clone5 treated with 10 uM Zebularine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Zebularine	Sample from drug screen treated with 10 µM Zebularine in position A02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM OG-L002	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM OG-L002	Sample from drug screen treated with 10 µM OG-L002 in position A03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM TMP269	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM TMP269	Sample from drug screen treated with 10 µM TMP269 in position A04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM ZM 39923 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM ZM 39923 HCl	Sample from drug screen treated with 10 µM ZM 39923 HCl in position A05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Veliparib (ABT-888)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Veliparib (ABT-888)	Sample from drug screen treated with 10 µM Veliparib (ABT-888) in position A06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM CX-6258 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CX-6258 HCl	Sample from drug screen treated with 10 µM CX-6258 HCl in position A07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM 2,4-Pyridinedicarboxylic Acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM 2,4-Pyridinedicarboxylic Acid	Sample from drug screen treated with 10 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM ITSA-1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM ITSA-1	Sample from drug screen treated with 10 µM ITSA-1 in position A09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM AGK2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AGK2	Sample from drug screen treated with 10 µM AGK2 in position A10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Oxamflatin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Oxamflatin	Sample from drug screen treated with 10 µM Oxamflatin in position A11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM 3-Deazaneplanocin A (DZNeP)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM 3-Deazaneplanocin A (DZNeP)	Sample from drug screen treated with 10 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC-CBP30	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SGC-CBP30	Sample from drug screen treated with 10 µM SGC-CBP30 in position B03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ004777	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM EPZ004777	Sample from drug screen treated with 10 µM EPZ004777 in position B04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM SMI-4a	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SMI-4a	Sample from drug screen treated with 10 µM SMI-4a in position B05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM FG-4592	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM FG-4592	Sample from drug screen treated with 10 µM FG-4592 in position B06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BMN 673	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BMN 673	Sample from drug screen treated with 10 µM BMN 673 in position B07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Garcinol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Garcinol	Sample from drug screen treated with 10 µM Garcinol in position B08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tranylcypromine hemisulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tranylcypromine hemisulfate	Sample from drug screen treated with 10 µM Tranylcypromine hemisulfate in position B09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Salermide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Salermide	Sample from drug screen treated with 10 µM Salermide in position B10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suramin 6Na	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Suramin·6Na	Sample from drug screen treated with 10 µM Suramin·6Na in position B11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ-6438	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM EPZ-6438	Sample from drug screen treated with 10 µM EPZ-6438 in position C02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM MM-102	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM MM-102	Sample from drug screen treated with 10 µM MM-102 in position C03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM OTX015	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM OTX015	Sample from drug screen treated with 10 µM OTX015 in position C04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX 01294	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BIX 01294	Sample from drug screen treated with 10 µM BIX 01294 in position C05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Panobinostat (LBH589)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Panobinostat (LBH589)	Sample from drug screen treated with 10 µM Panobinostat (LBH589) in position C06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM EPZ5676	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM EPZ5676	Sample from drug screen treated with 10 µM EPZ5676 in position C07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Splitomicin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Splitomicin	Sample from drug screen treated with 10 µM Splitomicin in position C08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Valproic acid	Sample from drug screen treated with 10 µM Valproic acid in position C09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM MC-1293	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM MC-1293	Sample from drug screen treated with 10 µM MC-1293 in position C10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-278	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BML-278	Sample from drug screen treated with 10 µM BML-278 in position C11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM C646	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM C646	Sample from drug screen treated with 10 µM C646 in position D02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGI-1027	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SGI-1027	Sample from drug screen treated with 10 µM SGI-1027 in position D03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC669	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM UNC669	Sample from drug screen treated with 10 µM UNC669 in position D04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM UPF 1069	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM UPF 1069	Sample from drug screen treated with 10 µM UPF 1069 in position D05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Trichostatin A (TSA)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Trichostatin A (TSA)	Sample from drug screen treated with 10 µM Trichostatin A (TSA) in position D06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM GSK J4 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM GSK J4 HCl	Sample from drug screen treated with 10 µM GSK J4 HCl in position D07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-210	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BML-210	Sample from drug screen treated with 10 µM BML-210 in position D08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Nicotinamide	Sample from drug screen treated with 10 µM Nicotinamide in position D09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Anacardic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Anacardic acid	Sample from drug screen treated with 10 µM Anacardic acid in position D10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM NCH-51	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM NCH-51	Sample from drug screen treated with 10 µM NCH-51 in position D11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM I-BET-762	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM I-BET-762	Sample from drug screen treated with 10 µM I-BET-762 in position E02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM RG2833 (RGFP109)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM RG2833 (RGFP109)	Sample from drug screen treated with 10 µM RG2833 (RGFP109) in position E03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM ME0328	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM ME0328	Sample from drug screen treated with 10 µM ME0328 in position E04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Scriptaid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Scriptaid	Sample from drug screen treated with 10 µM Scriptaid in position E05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Vorinostat (SAHA, MK0683)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Vorinostat (SAHA, MK0683)	Sample from drug screen treated with 10 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM SGC 0946	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM SGC 0946	Sample from drug screen treated with 10 µM SGC 0946 in position E07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Apicidin	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Apicidin	Sample from drug screen treated with 10 µM Apicidin in position E08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-266	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BML-266	Sample from drug screen treated with 10 µM BML-266 in position E09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM B2	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM B2	Sample from drug screen treated with 10 µM B2 in position E10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM NSC-3852	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM NSC-3852	Sample from drug screen treated with 10 µM NSC-3852 in position E11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM RGFP966	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM RGFP966	Sample from drug screen treated with 10 µM RGFP966 in position F02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM RVX-208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM RVX-208	Sample from drug screen treated with 10 µM RVX-208 in position F03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nexturastat A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Nexturastat A	Sample from drug screen treated with 10 µM Nexturastat A in position F04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Tubastatin A	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Tubastatin A	Sample from drug screen treated with 10 µM Tubastatin A in position F05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM VX-680 (Tozasertib, MK-0457)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM VX-680 (Tozasertib, MK-0457)	Sample from drug screen treated with 10 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM UNC1215	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM UNC1215	Sample from drug screen treated with 10 µM UNC1215 in position F07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Suberoyl bis-hydroxamic acid	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Suberoyl bis-hydroxamic acid	Sample from drug screen treated with 10 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Piceatannol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Piceatannol	Sample from drug screen treated with 10 µM Piceatannol in position F09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BIX-01294 3HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BIX-01294·3HCl	Sample from drug screen treated with 10 µM BIX-01294·3HCl in position F10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Aminoresveratrol sulfate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Aminoresveratrol sulfate	Sample from drug screen treated with 10 µM Aminoresveratrol sulfate in position F11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Bromosporine	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Bromosporine	Sample from drug screen treated with 10 µM Bromosporine in position G02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM PJ34 HCl	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM PJ34 HCl	Sample from drug screen treated with 10 µM PJ34 HCl in position G03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Filgotinib (GLPG0634)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Filgotinib (GLPG0634)	Sample from drug screen treated with 10 µM Filgotinib (GLPG0634) in position G04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Lomeguatrib	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Lomeguatrib	Sample from drug screen treated with 10 µM Lomeguatrib in position G05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Entinostat (MS-275)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Entinostat (MS-275)	Sample from drug screen treated with 10 µM Entinostat (MS-275) in position G06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM AZD1208	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM AZD1208	Sample from drug screen treated with 10 µM AZD1208 in position G07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Nullscript	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Nullscript	Sample from drug screen treated with 10 µM Nullscript in position G08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Fluoro-SAHA	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Fluoro-SAHA	Sample from drug screen treated with 10 µM Fluoro-SAHA in position G09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Butyrolactone 3	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Butyrolactone 3	Sample from drug screen treated with 10 µM Butyrolactone 3 in position G10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM BML-281	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM BML-281	Sample from drug screen treated with 10 µM BML-281 in position G11 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM IOX1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM IOX1	Sample from drug screen treated with 10 µM IOX1 in position H02 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM CPI-203	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CPI-203	Sample from drug screen treated with 10 µM CPI-203 in position H03 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Rocilinostat (ACY-1215)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Rocilinostat (ACY-1215)	Sample from drug screen treated with 10 µM Rocilinostat (ACY-1215) in position H04 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Pacritinib (SB1518)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Pacritinib (SB1518)	Sample from drug screen treated with 10 µM Pacritinib (SB1518) in position H05 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Olaparib (AZD2281, Ku-0059436)	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Olaparib (AZD2281, Ku-0059436)	Sample from drug screen treated with 10 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM (+)-JQ1	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM (+)-JQ1	Sample from drug screen treated with 10 µM (+)-JQ1 in position H07 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Isonicotinamide	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Isonicotinamide	Sample from drug screen treated with 10 µM Isonicotinamide in position H08 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Valproic acid hydroxamate	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Valproic acid hydroxamate	Sample from drug screen treated with 10 µM Valproic acid hydroxamate in position H09 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM CTPB	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM CTPB	Sample from drug screen treated with 10 µM CTPB in position H10 in plate 2
K562 ddCas9 RSTP2 clone5 treated with 10 uM Triacetylresveratrol	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5	Chronic Myeloid Leukemia	cell culture	LBR2	10 µM Triacetylresveratrol	Sample from drug screen treated with 10 µM Triacetylresveratrol in position H11 in plate 2
K562 ddCas9 RSTP2 pools treated with DMSO	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) pools	Chronic Myeloid Leukemia	cell culture	LBR2	DMSO	Sample from drug screen in position treated with  DMSO
K562 ddCas9 RSTP2 pools treated with Vorinostat	Homo sapiens	patient with chronic myelogenous leukemia (CML)	53	Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute	female	bone marrow	K562	K562-17 ddCas9 DSB-TRIP (RSTP2) pools	Chronic Myeloid Leukemia	cell culture	LBR2	Vorinostat	Sample from drug screen in position treated with  Vorinostat
